Subscribe to thousands of academic journals for just $40/month
Read and share the articles you need for your research, all in one place.

Quantitative Evaluation of Pharmacokinetic Inhibition of CYP3A Substrates by Ketoconazole: A Simulation Study

The Journal of Clinical Pharmacology , Volume 49 (3): 351 – Mar 1, 2009

Details

Publisher
Sage Publications
Copyright
Copyright © 2009 by SAGE Publications
ISSN
0091-2700
eISSN
0091-2700
D.O.I.
10.1177/0091270008331196
Publisher site
See Article on Publisher Site

Preview Only

Expand Tray Hide Tray

Quantitative Evaluation of Pharmacokinetic Inhibition of CYP3A Substrates by Ketoconazole: A Simulation Study

Abstract

The US Food and Drug Administration draft drug interaction guidance recommends that 400 mg ketoconazole (KTZ) be administered once daily for several days (QD400) for maximal CYP3A inhibition. Some investigators suggest that a single dose of 400 mg (SD400) KTZ is sufficient given its short half-life (t 1/2 ~ 3-5 hr). To determine the impact of KTZ regimens on CYP3A inhibition, we simulated AUC fold-change (AUCR) in the presence of SD400, QD400, or 200 mg twice-daily (BID200) KTZ for theoretical CYP3A substrates. Ratios of AUCR (AUCR QD400 /AUCR SD400 and AUCR BID200 AUCR QD400 ) increase with increasing bioavailability and increasing substrate t 1/2 . The SD400 KTZ regimen may provide maximal inhibition only for a subset of substrates (ie, low bioavailability and short t 1/2 ). For substrates with t 1/2 longer than that of KTZ, multiple KTZ dosing is critical and BID200 appears to provide greater inhibition than QD400. Also, timing of KTZ administration should be optimized to allow maximal presystemic enzyme inhibition prior to substrate administration.
Loading next page...

Preview Only. This article cannot be rented because we do not currently have permission from the publisher.

 
/lp/sage/quantitative-evaluation-of-pharmacokinetic-inhibition-of-cyp3a-ycx860y2rr